cbdMD's Regulatory Pivot: Kava Beverages and Cost Cuts to Weather the Hemp Shakeout

A Quarter of Contradictions

cbdMD's fiscal Q3 2026 was a study in contrasts. Top-line growth remained robust — net sales rose 20% year-over-year to $5.6 million — but the operating loss widened, a result CEO Ronan Kennedy describes as "largely by design." The company is deliberately investing in new product development, regulatory compliance, and M&A due diligence while simultaneously implementing a cost reduction program. The goal: emerge from the current regulatory chaos as a leaner, more diversified operator.

The strategic logic became clear during the call. With regulatory approval process uncertainty around hemp-derived THC intensifying, cbdMD is not waiting for the rules to settle. Instead, it's building optionality. The most visible move is the Oasis zero-proof Kava beverage launched on the call day. Kennedy emphasized: “Today is sort of the first day that, that product is available.” — T. Kennedy, Chief Executive Officer · 2026-08-13 Kava, a natural botanical with calming effects, is positioned as a compliant alternative to THC beverages, allowing cbdMD to retain shelf space even if regulations tighten.

cbdMD believes a ban on full-spectrum hemp-derived Delta-9 would be bad for public health. Demand exists, and as the saying goes, 'You can't put the toothpaste back in the tube.'

The company is also doubling down on wholesale — which grew 61% and now represents 30% of sales — and leveraging its recent Bluebird Botanicals acquisition. Kennedy remains confident in M&A, stating: “We are trying to drive cash – short-term cash flow as quickly as we – as quickly as possible, both in the core business and with any M&A that we pursue.” — T. Kennedy, Chief Executive Officer · 2026-08-13

Cost Discipline and a Path to Breakeven

The financial picture is a mix of deliberate spending and aggressive cost cutting. Gross margins slipped to 54.7% from 61.5% due to wholesale mix and one-time costs like repacking and inventory reserves. Operating expenses rose 12% to $4.2 million, but management expects a $100,000–$150,000 monthly reduction beginning in Q4. CFO Brad Whitford detailed the initiatives: payroll reductions, warehouse lease renegotiation, and vendor contract exits.

Kennedy was candid about the goal: "Our focus in the fourth quarter is on converting the revenue growth we are generating into improved contribution margin, lower fixed costs, and stronger adjusted EBITDA." The company projects a cash breakeven at roughly mid-$6 million quarterly revenue — down from the prior $7 million estimate. This aligns with the broader market's emphasis on commercial readiness and launch readiness in the face of shifting consumer and regulatory landscapes.

Despite the near-term losses, investors are likely to focus on the momentum in Oasis depletions, which hit a record in July, up 35% quarter-over-quarter. The Texas distribution expansion, which quadrupled store access, is already driving sell-through. With the Senate stopgap proposal and a growing slate of bipartisan bills (e.g., the Lawful Hemp Protection Act and the Beverage Regulatory Parity Act), cbdMD is positioning itself as a responsible operator that will benefit from rational regulation.

The company's fate now hinges on the legislative calendar. Section 781 takes effect November 12 unless Congress acts. But cbdMD is betting on a political climate where over 70% of voters favor sensible rules. As Kennedy put it: "We are generally encouraged by the growing leadership in Washington and by a widening slate of bipartisan bills."

In sum, cbdMD is not waiting for clarity; it is creating its own options. By launching Kava, cutting costs, and pursuing accretive M&A, the company is building the infrastructure to survive — and potentially thrive — regardless of how the regulatory dust settles. The immediate numbers are messy, but the strategic direction is unmistakable.